Open-angle glaucoma is linked to an increased risk for early-onset Alzheimer’s disease in middle-aged adults, especially men, ...

An international genetic study using multiancestry biobanks has identified novel genetic locations associated with primary open-angle glaucoma (POAG), the most common type of glaucoma and the leading ...

Open-angle glaucoma represents one of the most prevalent causes of irreversible sight loss globally. The principal aim of treatment is to lower intraocular pressure (IOP) to slow the progression of ...

Glaucoma often progresses without symptoms until vision loss is permanent. Experts outline seven early warning signs and ...

Qlaris Bio is seeing double when it comes to phase 2 wins for its eye drug, hitting the primary endpoints in trials that both spanned primary open angle glaucoma (POAG) and ocular hypertension (OHT).

A new glaucoma drug, latanoprostene bunod (LBN) ophthalmic solution 0.024% (Vyzulta™), was approved by the US Food and Drug Administration in November 2017. Key to its approval was the VOYAGER Study.

DEAR DR. ROACH: I am a 77-year-old woman in good health. I walk daily. The only prescribed medications I am on are two different eye drops for glaucoma. My eye pressure is under control; I have it ...

PXG patients exhibited faster GCIPL and RNFL thinning rates than POAG and control groups, indicating more severe progression. The study involved 180 participants, divided into POAG, PXG, and control ...